Tissue Diagnostics Market by Product (Consumables, Instruments), Technology (Immunohistochemistry, in Situ Hybridization, Digital Pathology & Workflow), Disease (Breast Cancer, Gastric Cancer, Lymphoma), End User (Hospital, CRO) - Global Forecast to 2022
[160 Pages Report] The tissue diagnostics market is expected to reach USD 5.14 Billion by 2022 from USD 3.44 Billion in 2016 at a CAGR of 6.9%. The base year for this study is 2016 and the forecast period is 20172022.
Market Dynamics
Rising incidence of cancer
Over the last few decades, there has been a significant increase in cancer incidence in major regions across the globe. According to GLOBOCAN, ~14.1 million new cancer cases and 8.2 million cancer-related deaths were recorded globally in 2012. These figures are estimated to increase to 17.1 million new cases and 10.0 million cancer-related deaths, globally, by 2020. Based on GLOBOCANs statistics, the International Agency for Research on Cancer (ICRA) and the World Health Organization (WHO) have estimated that by 2025, around 19.3 million new cancer cases will be diagnosed every year. This surge in the number of new cancer cases can primarily be attributed to the rising geriatric population.
The population aged 60 years and over is expected to almost double from about 12% of the total global population in 2015 to 22% by 2050; the number of people aged over 60 years will increase from 900 million to 2 billion over the same period (Source: WHO). As the elderly are more susceptible to various diseases, this demographic trend is expected to result in a significant growth in the prevalence of several chronic diseases across the globe. For instance, non-communicable diseases (heart diseases, cancer, and diabetes) account for about 87% of the disease burden in the aged population in low-, middle-, and high-income countries. Moreover, people aged over 65 years account for close to 60% of all new cancer cases and close to 70% of all cancer deaths. The American Cancer Society reported in 2015 that across the globe, there would be 13 million cancer deaths on account of the aging population. The age-adjusted cancer incidence rate is 208/100,000 for people aged below 65 years and 2,151/100,000 for people aged over 65 years, representing a ten-fold increase.
High degree of consolidation
The tissue diagnostics market is highly consolidated, with five players holding a share of close to 80%. This includes tier-I companies such as Roche (Switzerland), Danaher (US), Agilent Technologies (US), Abbott (US), and Thermo Fisher Scientific (US). The remaining 20% of the market is fragmented, with a wide range of players operating in niche market segments in the reagents, consumables, and accessories space. High capital investments for R&D and manufacturing of tissue diagnostic products further restrict the entry of new market players.
The top five players in this market are well-established and enjoy a high degree of brand loyalty. As a result, it is difficult for new entrants in this market to compete with existing players and differentiate themselves with innovative product offerings. The major entry barriers for new entrants are in turn expected to restrict investments and thus the growth potential of this market.
Growing demand for personalized medicine
The increasing pressure to identify diagnostic markers for cancer in order to customize treatment plans for individual patients is expected to increase the usage of personalized medicine for cancer. Tissue diagnostics enables the identification of these cancer markers, and several tissue diagnostics kits are being investigated as companion diagnostics for cancer therapies. Thus, the growing use of personalized medicine is expected to support the growth of the tissue diagnostics market. Similarly, in vitro diagnostic reagents, test products, instrumentation, and other related products, which are widely used by both clinical and research laboratories, are an integral part of the development of personalized medicine. As a result, the growth in the overall in vitro diagnostic (IVD) market (this market was valued at USD 60.22 billion in 2016 and is estimated to grow at an annual growth rate of 5.5% over the next five years) is expected to support the growth of the tissue diagnostics market (as tissue diagnostics is a part of in vitro diagnostics).
Lack of infrastructure and low awareness in middle- and low- income countries
The burden of cancer and other non-communicable diseases is very high in developing and underdeveloped countries. However, there is a glaring disparity in the access to care and health indicators in these countries as compared to their developed counterparts. This can be attributed to the lack of access to care; lesser availability of resources in terms of infrastructure and manpower; lack of awareness; and the social stigma associated with cancer. As per proceedings of the European Congress of Pathology, 2016, countries in Southeast Asia, Western Pacific, and Africa have a critical shortage of healthcare providers, requiring an increase in capacity by 50%, 119%, and 139%, respectively. Similarly, the 2017 report of the Breast Cancer Initiative 2.5 by the Fred Hutchinson Cancer Research Center (US) stated that there is a demand-supply gap for diagnostic services for breast cancer in middle- and low-income countries on account of high demand; workforce shortage; underfunded and under-resourced laboratories; and limited training. These challenges can potentially affect the growth prospects of the tissue diagnostics market in these countries.
The objectives of this study are as follows:
- To define, describe, segment, and forecast the market by product, technology, disease, end user, and region
- To forecast revenue of the market segments with respect to four main regional segments, namely, North America, Europe, Asia, and the Rest of the World (RoW)
- To identify the micromarkets with respect to drivers, restraints, industry-specific challenges, opportunities, and trends affecting the growth of the market
- To analyze market segments and subsegments with respect to individual growth trends, prospects, and contributions to the overall market
- To analyze opportunities in the market for stakeholders and provide details of the competitive landscape for market leaders
- To profile the key players and comprehensively analyze their market shares and core competencies in terms of market developments and growth strategies
- To track and analyze competitive developments such as partnerships, agreements, collaborations, and joint ventures; mergers and acquisitions; product launches; and research and development activities in the tissue diagnostics market
Research Methodology
Top-down and bottom-up approaches were used to estimate and validate the size of the market and to estimate the size of various other dependent submarkets. The overall market size was used in the top-down approach to estimate the sizes of other individual submarkets (mentioned in the market segmentation by product, technology, disease, end user, and region) through percentage splits from secondary and primary research. The bottom-up approach was also implemented (wherever applicable) for data extracted from secondary research to validate the market segment revenues obtained. Various secondary sources such as World Health Organization, National Institutes of Health, Eurostat, U.S. Food and Drug Administration, Centers for Disease Control and Prevention, European Diagnostic Manufacturers Association, GLOBOCAN, World Bank, World Cancer Research Fund International, American Cancer Society, American Association for Clinical Chemistry, European Commission, and European Centre for Disease Prevention and Control have been used to identify and collect information useful for this extensive commercial study of the market. Primary sources such as experts from related industries and suppliers have been interviewed to obtain and verify critical information as well as to assess prospects of the market. The breakdown of profiles of primaries is shown in the figure below:
To know about the assumptions considered for the study, download the pdf brochure
The key players in the tissue diagnostics include Roche (Switzerland), Danaher (US), Thermo Fisher Scientific (US), Abbott (US), Agilent Technologies (US), Merck (Germany), Sakura Finetek Japan (Japan), Abcam (UK), BD (US), QIAGEN (Netherlands), Sienna Cancer Diagnostics (Australia), Royal Philips (Netherlands), A. Menarini Diagnostics (Italy), Cell Signaling Technology (US), Enzo Life Sciences (US), Master Diagnσstica (Spain), TissueGnostics (Austria), Bio SB (US), MedImmune (US), Cernostics (US), Zenalux Biomedical (US), 3DHISTECH (Hungary), Lunaphore Technologies (Switzerland), BioGenex (US), and Biocare Medical (US).
Target Audience for this Report:
- Manufacturers and vendors of tissue diagnostics equipment
- Research associations related to tissue diagnostics
- Pathologists and pathology laboratories
- Various research and consulting firms
- Distributors of tissue diagnostics equipment
- Contract research manufacturers of tissue diagnostics equipment
- Government bodies
- Tissue diagnostics database and software providers
- Venture capitalists
Scope of the Report:
This report categorizes the tissue diagnostics market into the following segments:
By Product
- Consumables
- Antibodies
- Kits
- Reagents
- Probes
- Instruments
- Slide-staining systems
- Scanners
- Tissue-processing systems
- Other instruments
By Technology
- Immunohistochemistry
- In situ hybridization
- Digital pathology and workflow management
- Special staining
By Disease
- Breast cancer
- Gastric cancer
- Lymphoma
- Prostate cancer
- Non-small cell lung cancer
- Other diseases
By End User
- Hospitals
- Pharmaceutical companies
- Research laboratories
- Contract research organizations
- Other end users
By Region
- North America
- US
- Canada
- Europe
- Germany
- France
- UK
- Italy
- Spain
- Rest of Europe
- Asia
- Japan
- China
- India
- Rest of Asia
- Rest of the World
Customization Options:
- Company Information: Detailed company profiles of five or more market players
- Opportunities Assessment: A detailed report underlining the various growth opportunities presented in the tissue diagnostics market
The growing incidence of cancer along with a rapidly aging population, technological advancements in tissue diagnostics techniques, and increasing healthcare expenditure are key factors driving the growth of the market.
The global tissue diagnostics market is segmented by product, technology, disease, end user, and regions. By product, the market is segmented into instruments and consumables. The consumables segment is estimated to account for the largest market share of the global market in 2017. Factors driving the growth of this segment include the widespread use of consumables and advances in technology to develop novel consumables.
By technology, the market is classified into immunohistochemistry, in situ hybridization, digital pathology and workflow, and special staining. The immunohistochemistry segment is estimated to account for the largest share of the global market during the next five years. Growth in the IVD (in vitro diagnostics) market and the large number of products based on this technology are driving the growth of this market.
On the basis of end user, the market is segmented into hospitals, pharmaceutical companies, research laboratories, contract research organizations, and other end users. The hospitals segment is estimated to account for the largest share of the global market during the forecast period. Growth in the number of hospitals coupled with better accessibility and availability of test results in hospitals are major factors driving the growth of this end-user segment.
The global tissue diagnostics market is dominated by North America, followed by Europe. North America will continue to dominate the global market during the forecast period. However, Asia is expected to witness the highest CAGR during the forecast period with growth centered at Japan, China, and India. Factors such as the rising focus of major players in emerging Asian countries and government support are driving the growth of the market in this region.
The factors such as the high degree of consolidation, the high cost of instruments, and complex regulatory framework for the approval of new products may restrain market growth to a certain extent.
Major industry players launched innovative products to maintain and improve their position in the market. Roche (Switzerland), Danaher (US), Thermo Fisher Scientific (US), Abbott (US), Agilent Technologies (US), Merck (Germany), and Sakura Finetek Japan (Japan) have been identified as the key players in Tissue Diagnostics Market. These companies have a broad product portfolio with comprehensive features and have also launched innovative products. These leaders have products for all end users in this market, a strong geographical presence, and focus on continuous product innovations.
To speak to our analyst for a discussion on the above findings, click Speak to Analyst
Table of Contents
1 Introduction (Page No. - 15)
1.1 Objectives of the Study
1.2 Tissue Diagnostics Market Definition
1.3 Market Scope
1.3.1 Markets Covered
1.3.2 Years Considered for the Study
1.4 Currency
1.5 Limitations
1.6 Stakeholders
2 Research Methodology (Page No. - 18)
2.1 Research Data
2.1.1 Secondary Data
2.1.1.1 Key Data From Secondary Sources
2.1.2 Primary Data
2.1.2.1 Key Data From Primary Sources
2.1.2.2 Breakdown of Primaries
2.2 Tissue Diagnostics Market Size Estimation
2.2.1 Bottom-Up Approach
2.2.2 Top-Down Approach
2.3 Market Breakdown and Data Triangulation
2.4 Research Assumptions
3 Executive Summary (Page No. - 26)
4 Premium Insights (Page No. - 30)
4.1 Tissue Diagnostics Market: Overview
4.2 Geographic Analysis: Market in Asia, By Country and Technology
4.3 Global Market, By End User
4.4 Geographical Snapshot of the Global Market
5 Market Overview (Page No. - 34)
5.1 Introduction
5.2 Tissue Diagnostics Market Dynamics
5.2.1 Drivers
5.2.1.1 Rising Incidence of Cancer
5.2.1.2 Growing Healthcare Expenditure
5.2.1.3 Improving Infrastructure for Cancer Diagnosis
5.2.1.4 Technological Advancements in Tissue Diagnostics
5.2.2 Restraints
5.2.2.1 High Degree of Consolidation
5.2.3 Opportunities
5.2.3.1 Emerging Markets
5.2.3.2 Growing Demand for Personalized Medicine
5.2.3.3 Rising Number of Clinical Trials for Cancer Drugs
5.2.4 Challenges
5.2.4.1 Stringent Regulatory Requirements
5.2.4.2 Lack of Infrastructure and Low Awareness in Middle- and Low- Income Countries
5.2.5 Trends
5.2.5.1 Increasing Number of Reagent Rental Agreements
6 Tissue Diagnostics Market, By Product (Page No. - 41)
6.1 Introduction
6.2 Consumables
6.2.1 Antibodies
6.2.2 Kits
6.2.3 Reagents
6.2.4 Probes
6.3 Instruments
6.3.1 Slide-Staining Systems
6.3.2 Scanners
6.3.3 Tissue-Processing Systems
6.3.4 Other Instruments
7 By Technology (Page No. - 51)
7.1 Introduction
7.2 Immunohistochemistry (IHC)
7.3 in Situ Hybridization (ISH)
7.4 Digital Pathology and Workflow Management
7.5 Special Staining
8 By Disease (Page No. - 58)
8.1 Introduction
8.2 Breast Cancer
8.3 Gastric Cancer
8.4 Lymphoma
8.5 Prostate Cancer
8.6 Non-Small Cell Lung Cancer (NSCLC)
8.7 Other Diseases
9 By End User (Page No. - 66)
9.1 Introduction
9.2 Hospitals
9.3 Research Laboratories
9.4 Pharmaceutical Companies
9.5 Contract Research Organizations
9.6 Other End Users
10 By Region (Page No. - 73)
10.1 Introduction
10.2 North America
10.2.1 US
10.2.2 Canada
10.3 Europe
10.3.1 Germany
10.3.2 UK
10.3.3 France
10.3.4 Italy
10.3.5 Spain
10.3.6 Rest of Europe (RoE)
10.4 Asia
10.4.1 China
10.4.2 Japan
10.4.3 India
10.4.4 Rest of Asia (RoA)
10.5 Rest of the World (RoW)
11 Competitive Landscape (Page No. - 121)
11.1 Introduction
11.2 Tissue Diagnostics Market Share Analysis
12 Company Profiles (Page No. - 123)
(Business Overview, Strength of Product Portfolio, Business Strategy Excellence, Recent Developments,)*
12.1 Roche
12.2 Danaher
12.3 Thermo Fisher Scientific
12.4 Abbott
12.5 Agilent Technologies
12.6 Merck
12.7 Sakura Finetek Japan
12.8 Abcam
12.9 BD
12.10 Qiagen
12.11 Bio SB
12.12 Biogenex
12.13 Cell Signaling Technology
*Details on Business Overview, Strength of Product Portfolio, Business Strategy Excellence, Recent Developments, Might Not Be Captured in Case of Unlisted Companies.
13 Appendix (Page No. - 152)
13.1 Industry Insights
13.2 Discussion Guide
13.3 Knowledge Store: Marketsandmarkets Subscription Portal
13.4 Introducing RT: Real-Time Market Intelligence
13.5 Available Customizations
13.6 Related Reports
13.7 Author Details
List of Tables (96 Tables)
Table 1 Tissue Diagnostics: Market Snapshot
Table 2 Tissue Diagnostics Market, By Product, 20152022 (USD Million)
Table 3 Market for Consumables, By Type, 20152022 (USD Million)
Table 4 Market for Consumables, By Region, 20152022 (USD Million)
Table 5 Market for Antibodies, By Region, 20152022 (USD Million)
Table 6 Market for Kits, By Region, 20152022 (USD Million)
Table 7 Tissue Diagnostics Market for Reagents, By Region, 20152022 (USD Million)
Table 8 Market for Probes, By Region, 20152022 (USD Million)
Table 9 Market for Instruments, By Type, 20152022 (USD Million)
Table 10 Market for Instruments, By Region, 20152022 (USD Million)
Table 11 Market for Slide-Staining Systems, By Region, 20152022 (USD Million)
Table 12 Market for Scanners, By Region, 20152022 (USD Million)
Table 13 Market for Tissue-Processing Systems, By Region, 20152022 (USD Million)
Table 14 Market for Other Instruments, By Region, 20152022 (USD Million)
Table 15 Market, By Technology, 2015-2022 (USD Million)
Table 16 Tissue Diagnostics Market for Immunohistochemistry, By Region, 2015-2022 (USD Million)
Table 17 Market for in Situ Hybridization, By Region, 2015-2022 (USD Million)
Table 18 Market for Digital Pathology and Workflow Management, By Region, 2015-2022 (USD Million)
Table 19 Market for Special Staining, By Region, 2015-2022 (USD Million)
Table 20 Market, By Disease, 20152022 (USD Million)
Table 21 Market for Breast Cancer, By Region, 20152022 (USD Million)
Table 22 Tissue Diagnostics Market for Gastric Cancer, By Region, 20152022 (USD Million)
Table 23 Market for Lymphoma, By Region, 20152022 (USD Million)
Table 24 Market for Prostate Cancer, By Region, 20152022 (USD Million)
Table 25 Market for Non-Small Cell Lung Cancer, By Region, 20152022 (USD Million)
Table 26 Market for Other Diseases, By Region, 20152022 (USD Million)
Table 27 Tissue Diagnostics Market, By End User, 20152022 (USD Million)
Table 28 Market for Hospitals, By Region, 20152022 (USD Million)
Table 29 Market for Research Laboratories, By Region, 20152022 (USD Million)
Table 30 Market for Pharmaceutical Companies, By Region, 20152022 (USD Million)
Table 31 Market for Contract Research Organizations, By Region, 20152022 (USD Million)
Table 32 Tissue Diagnostics Market for Other End Users, By Region, 20152022 (USD Million)
Table 33 Market, By Region, 20152022 (USD Million)
Table 34 North America: Market, By Country, 20152022 (USD Million)
Table 35 North America: Market, By Product, 20152022 (USD Million)
Table 36 North America: Market for Consumables, By Type, 20152022 (USD Million)
Table 37 North America: Market for Instruments, By Type, 20152022 (USD Million)
Table 38 North America: Market, By Disease, 20152022 (USD Million)
Table 39 North America: Market, By Technology, 20152022 (USD Million)
Table 40 North America: Market, By End User, 20152022 (USD Million)
Table 41 US: Market, By Product, 20152022 (USD Million)
Table 42 US: Market, By Technology, 20152022 (USD Million)
Table 43 US: Market, By End User, 20152022 (USD Million)
Table 44 Canada: Tissue Diagnostics Market, By Product, 20152022 (USD Million)
Table 45 Canada: Market, By Technology, 20152022 (USD Million)
Table 46 Canada: Market, By End User, 20152022 (USD Million)
Table 47 Europe: Tissue Diagnostics Market, By Country, 20152022 (USD Million)
Table 48 Europe: Market, By Product, 20152022 (USD Million)
Table 49 Europe: Market for Consumables, By Type, 20152022 (USD Million)
Table 50 Europe: Market for Instruments, By Type, 20152022 (USD Million)
Table 51 Europe: Market, By Disease, 20152022 (USD Million)
Table 52 Europe: Market, By Technology, 20152022 (USD Million)
Table 53 Europe: Market, By End User, 20152022 (USD Million)
Table 54 Germany: Market, By Product, 20152022 (USD Million)
Table 55 Germany: Market, By Technology, 20152022 (USD Million)
Table 56 Germany: Market, By End User, 20152022 (USD Million)
Table 57 UK: Market, By Product, 20152022 (USD Million)
Table 58 UK: Market, By Technology, 20152022 (USD Million)
Table 59 UK: Market, By End User, 20152022 (USD Million)
Table 60 France: Tissue Diagnostics Market, By Product, 20152022 (USD Million)
Table 61 France: Market, By Technology, 20152022 (USD Million)
Table 62 France: Market, By End User, 20152022 (USD Million)
Table 63 Italy: Tissue Diagnostics Market, By Product, 20152022 (USD Million)
Table 64 Italy: Market, By Technology, 20152022 (USD Million)
Table 65 Italy: Market, By End User, 20152022 (USD Million)
Table 66 Spain: Market, By Product, 20152022 (USD Million)
Table 67 Spain: Market, By Technology, 20152022 (USD Million)
Table 68 Spain: Market, By End User, 20152022 (USD Million)
Table 69 RoE: Market, By Product, 20152022 (USD Million)
Table 70 RoE: Market, By Technology, 20152022 (USD Million)
Table 71 RoE: Market, By End User, 20152022 (USD Million)
Table 72 Asia: Tissue Diagnostics Market, By Country, 20152022 (USD Million)
Table 73 Asia: Market, By Product, 20152022 (USD Million)
Table 74 Asia: Market for Consumables, By Type, 20152022 (USD Million)
Table 75 Asia: Market for Instruments, By Type, 20152022 (USD Million)
Table 76 Asia: Market, By Disease, 20152022 (USD Million)
Table 77 Asia: Market, By Technology, 20152022 (USD Million)
Table 78 Asia: Market, By End User, 20152022 (USD Million)
Table 79 China: Tissue Diagnostics Market, By Product, 20152022 (USD Million)
Table 80 China: Market, By Technology, 20152022 (USD Million)
Table 81 China: Market, By End User, 20152022 (USD Million)
Table 82 Japan: Market, By Product, 20152022 (USD Million)
Table 83 Japan: Market, By Technology, 20152022 (USD Million)
Table 84 Japan: Market, By End User, 20152022 (USD Million)
Table 85 India: Market, By Product, 20152022 (USD Million)
Table 86 India: Market, By Technology, 20152022 (USD Million)
Table 87 India: Market, By End User, 20152022 (USD Million)
Table 88 RoA: Market, By Product, 20152022 (USD Million)
Table 89 RoA: Market, By Technology, 20152022 (USD Million)
Table 90 RoA: Market, By End User, 20152022 (USD Million)
Table 91 RoW: Tissue Diagnostics Market, By Product, 20152022 (USD Million)
Table 92 RoW: Market for Consumables, By Type, 20152022 (USD Million)
Table 93 RoW: Market for Instruments, By Type, 20152022 (USD Million)
Table 94 RoW: Market, By Disease, 20152022 (USD Million)
Table 95 RoW: Market, By Technology, 20152022 (USD Million)
Table 96 RoW: Market, By End User, 20152022 (USD Million)
List of Figures (40 Figures)
Figure 1 Research Design
Figure 2 Breakdown of Primary Interviews: By Company Type, Designation, and Region
Figure 3 Market Size Estimation Methodology: Bottom-Up Approach
Figure 4 Tissue Diagnostics Market Size Estimation Methodology: Top-Down Approach
Figure 5 Data Triangulation Methodology
Figure 6 Market, By Product, 20172022 (USD Billion)
Figure 7 Global Market, By Technology, 20172022 (USD Billion)
Figure 8 Market, By Disease, 20172022 (USD Billion)
Figure 9 Global Market, By End User, 20172022 (USD Billion)
Figure 10 Global Market, By Region, 20172022 (USD Billion)
Figure 11 Rising Incidence of Cancer to Drive the Growth of the Market During the Forecast Period
Figure 12 Immunohistochemistry to Dominate the Tissue Diagnostics Market in Asia in 2017
Figure 13 Research Laboratories Will Register the Highest CAGR During the Forecast Period
Figure 14 Asia to Register the Highest CAGR During the Forecast Period
Figure 15 Market: Drivers, Restraints, Opportunities, Challenges, and Trends
Figure 16 Global Healthcare Spending, 20042014
Figure 17 Growth in Per Capita Healthcare Expenditure in Brics Countries, 20042014
Figure 18 Consumables Segment to Dominate the Global Tissue Diagnostics Products Market in 2017
Figure 19 Immunohistochemistry to Dominate the Tissue Diagnostics Technology Market During the Forecast Period
Figure 20 Tissue Diagnostics Market, By Disease, 2017 vs 2022 (USD Million)
Figure 21 Global Market, By End User, 2017 vs 2022 (USD Million)
Figure 22 Market in Asia to Witness the Highest Growth During the Forecast Period
Figure 23 North America: Market Snapshot
Figure 24 Consumables to Command the Largest Share of the Market in North America During the Forecast Period
Figure 25 Europe: Market Snapshot
Figure 26 Breast Cancer to Form the Largest Disease Segment in Europe in 2017
Figure 27 Asia: Market Snapshot
Figure 28 Immunohistochemistry to Form the Largest Technology Segment in Asia in 2017
Figure 29 RoW: Market Snapshot
Figure 30 Hospitals to Form the Largest End-User Segment in RoW in 2017
Figure 31 Global: Market Share (2016)
Figure 32 Roche: Company Snapshot
Figure 33 Danaher: Company Snapshot
Figure 34 Thermo Fisher Scientific: Company Snapshot
Figure 35 Abbott: Company Snapshot
Figure 36 Agilent Technologies: Company Snapshot
Figure 37 Merck: Company Snapshot
Figure 38 Abcam: Company Snapshot
Figure 39 BD: Company Snapshot
Figure 40 Qiagen : Company Snapshot
- Triangulate with your Own Data
- Get Data as per your Format and Definition
- Gain a Deeper Dive on a Specific Application, Geography, Customer or Competitor
- Any level of Personalization
- What are the Known and Unknown Adjacencies Impacting the Tissue Diagnostics Market
- What will your New Revenue Sources be?
- Who will be your Top Customer; what will make them switch?
- Defend your Market Share or Win Competitors
- Get a Scorecard for Target Partners
Growth opportunities and latent adjacency in Tissue Diagnostics Market